More Protocols And Guidance Are Needed As Momentum Builds For Veterans, Psychedelics, And Mental Health
Portfolio Pulse from Andre Bourque
Research indicates a significant percentage of U.S. veterans suffer from mental health disorders, with psychedelics showing promise in treatment. The FDA has granted breakthrough therapy designations to psilocybin and MDMA, signaling potential approval for therapeutic use. Congress is considering directing the Defense Department to study psychedelics for PTSD treatment. The VA has updated guidelines to include ketamine and esketamine but not other psychedelics. Cybin Inc. (AMEX:CYBN) has developed EMBARK, a psychological support model, and is testing synthetic psychedelic compounds CYB003 and CYB004 for MDD and GAD, respectively, with promising results. There is a call for the VA to provide guidance on psychedelic therapies to match private sector advancements.
December 13, 2023 | 5:56 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cybin Inc. is advancing psychedelic compounds CYB003 and CYB004 for MDD and GAD treatment, with CYB003 showing significant reduction in depression symptoms. The company's EMBARK model provides a framework for psychedelic drug support.
Cybin Inc.'s positive study results and the development of the EMBARK model, combined with the growing acceptance of psychedelics for mental health treatment, could lead to increased investor interest and potential stock price appreciation in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100